Although not specific to this disease, several blood-based biomarkers, such as serum ferritin, YKL-40, neopterin, KL-6, SP-D, IL18, and IFN-α, as well as antibody biomarkers, such as the Anti-Ro52 antibody or autoantibodies, and the circulating immune cell biomarker CD3+T cell can aid in the early diagnosis, prognosis, and treatment efficacy of DM-RPILD. Here, MUC1 is linked to dermatomyositis.